The startup develops vascular-targeted biotherapeutics that utilize antibody-drug conjugates to deliver therapeutic payloads directly to the nuclei of tumor cells and activated endothelial cells in solid cancers. This approach aims to enhance treatment efficacy for aggressive cancers such as pancreatic, lung, and liver cancers, as well as glioblastoma multiforme.
Funding
$76M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid cancers, including pancreatic, lung, and liver cancers, as well as glioblastoma multiforme, are aggressive and difficult to treat effectively with existing therapies. These cancers often exhibit resistance to conventional treatments and have a high mortality rate.
Solution
Angiex is developing Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that target the TM4SF1 protein, which is highly expressed in both tumor cells and the endothelial cells of tumor blood vessels across most solid cancers. Angiex's Nuclear Delivery Platform™ delivers chemotherapeutic payloads directly to the nucleus of these cells, offering the potential for enhanced efficacy and a wider therapeutic margin. The lead ND-ADC, AGX101, is currently in Phase 1 clinical trials for patients with unresectable, locally advanced, or metastatic solid tumors. This approach aims to overcome cancer's suppression of immune defense, angiogenesis, and invasion and metastasis. By selectively delivering payloads to TM4SF1-expressing cells, Angiex's ND-ADCs may minimize delivery to healthy tissue, potentially reducing common cancer therapy side effects.
Target Audience
The primary target audience includes patients with unresectable, locally advanced, or metastatic solid tumors, as well as pharmaceutical partners and investors interested in novel cancer therapeutics.
Features
- Nuclear Delivery Platform™ consisting of proprietary TM4SF1-directed antibodies, site-specific conjugation method, and linkers
- AGX101, a TM4SF1-directed antibody conjugated with a microtubule inhibitor, currently in Phase 1 clinical trials (NCT06440005)
- Three mechanisms of action: activation of anti-tumor immunity, obliteration of tumor vessels, and tumor cell killing
- Potential to treat a wide range of solid cancers due to broad TM4SF1 expression
- Ability to conjugate a wide range of drug payloads, including traditional chemotherapies, targeted small molecules, protein degraders, and RNA
- Enhanced efficacy by giving drug payloads direct access to nuclear and cytosolic targets
- Minimized common cancer therapy side effects by delivering drug payloads only to TM4SF1 expressing cells